The strategy of piking a target: What is aktually most effective?

Research output: Contribution to journalArticle

Abstract

Breast and gynecologic cancers harboring PIK3CA mutations showed no significant responses to AZD5363, a pan-AKT catalytic inhibitor, in contrast with previous in vitro data showing activity of the drug in this subset of cancers. These results raise the question of how to select the most accurate predictive biomarkers of response.

Details

Authors
Organisations
External organisations
  • Massachusetts General Hospital
  • Harvard Medical School
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)2029-2031
Number of pages3
JournalClinical Cancer Research
Volume24
Issue number9
StatePublished - 2018 May 1
Peer-reviewedYes